Most Read Articles
4 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pearl Toh, 25 Jun 2020
The type of face mask matters, in addition to sterilization method, in influencing subsequent filtration efficiency after sterilization process for reuse, a new study finds.
17 hours ago
A recent survey reports acceptable dispensing of naloxone among pharmacists that serviced San Francisco safety net clinics.
3 days ago
Cardiovascular (CV) risk prediction algorithms tend to be inaccurate, frequently underestimating and sometimes overestimating the risk of CV in patients with inflammatory rheumatic diseases, a recent study has shown.

Product Highlight - Xarelto

25 Jun 2020
The First & Only NOAC Approved for CAD/PAD1*
Xarelto, co-administered with ASA, is indicated for the prevention of atherothrombotic events in adult patients with CAD or symptomatic PAD at high risk of ischaemic events.2

In the COMPASS trial, Xarelto 2.5 mg bid + aspirin vs aspirin alone:
• -24% primary outcome: CV death, stroke or MI (p<0.001)3
• -23% all-cause mortality in CAD patients (p=0.0012)4
• -46% MALE and major amputations in PAD patients (p=0.0037)5
• No significant increase in the risk of most serious bleeding3
• Recommended by the 2019 ESC6 and ESVM7 Guidelines

ASA: acetylsalicylic acid; CAD: coronary artery disease; CV: cardiovascular; ESC: European Society of Cardiology; ESVM: European Society for Vascular Medicine; MALE: major adverse limb events; MI: myocardial infarction; NOAC: non-vitamin K oral anticoagulant; PAD: peripheral artery disease.

*As of Apr 1, 2020

References:
1. U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) [news release]. Titusville, NJ; October 11, 2018: Janssen Pharmaceuticals website. https://www.janssen.com/us-fda-approves-xareltor-rivaroxaban-reduce-risk-major-cardiovascular-events-patients-chronic. Accessed Apr 1, 2020.
2. Xarelto Hong Kong prescribing information.
3. Eikelboom JW, et al. N Engl J Med 2017;377:1319–1330.
4. Connolly SJ, et al. Lancet 2017; doi: 10.1016/S0140–6736(17)32458–3.
5. Anand SS, et al. J Am Coll Cardiol 2019;73:3271–80.
6. Neumann FJ, et al. European Heart Journal (2019) 00, 1-71. doi:10.1093/eurheartj/ehz425.
7. Frank U, et al. Vasa (2019), 48 (Supplement 102).


 

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pearl Toh, 25 Jun 2020
The type of face mask matters, in addition to sterilization method, in influencing subsequent filtration efficiency after sterilization process for reuse, a new study finds.
17 hours ago
A recent survey reports acceptable dispensing of naloxone among pharmacists that serviced San Francisco safety net clinics.
3 days ago
Cardiovascular (CV) risk prediction algorithms tend to be inaccurate, frequently underestimating and sometimes overestimating the risk of CV in patients with inflammatory rheumatic diseases, a recent study has shown.